丹麦全国队列:老年人常用抗抑郁药真实世界临床结局
该研究基于丹麦全国登记数据,纳入2006至2017年间首次因抑郁启用抗抑郁药的93,883名老年人(平均年龄78.0岁),分析10种最常用抗抑郁药1年内的临床结局。以舍曲林为参照,多数其他抗抑郁药的停药、换药、增量、心血管事件和死亡风险显著更高,米氮平和文拉法辛结局最差。
要点
- 以舍曲林为参照,米氮平停药风险IRR=1.55(95%CI=1.50-1.61),文拉法辛停药风险IRR=1.22(95%CI=1.12-1.32)。
- 阿米替林换药风险IRR=1.45(95%CI=1.15-1.81),文拉法辛换药风险IRR=1.47(95%CI=1.20-1.80)。
- 米氮平和文拉法辛使用者相比舍曲林使用者不良结局最多,性别和年龄分层结果一致。
核心结论
- 老年人首次使用常用抗抑郁药的临床结局存在差异,米氮平和文拉法辛相比舍曲林不良结局最多。
研究设计与样本
- 基于丹麦全国登记数据的队列研究,纳入2006至2017年间首次因抑郁启用抗抑郁药的老年人,仅分析10种最常领取的抗抑郁药。
主要发现
- 样本共93,883名老年人,平均年龄78.0岁(SD=7.5岁),56%为女性。
- 最常处方者为西酞普兰(47.04%)、米氮平(22.87%)、艾司西酞普兰(11.81%)和舍曲林(11.17%)。
- 相比舍曲林使用者,多数其他九种抗抑郁药使用者的停药、换药、增量、心血管事件和死亡风险显著更高。
- 米氮平停药IRR=1.55(95%CI=1.50-1.61),文拉法辛停药IRR=1.22(95%CI=1.12-1.32)。
- 阿米替林换药IRR=1.45(95%CI=1.15-1.81),文拉法辛换药IRR=1.47(95%CI=1.20-1.80)。
关键数值与推荐
- 以舍曲林为参照药物,因丹麦指南推荐其作为抑郁一线治疗。
- 结局包括停药、换药、增量、精神科住院接触、自杀未遂或自伤、跌倒相关损伤、心血管事件和全因死亡。
- 采用泊松回归模型估计发生率比(IRR)及95%置信区间,并控制潜在混杂因素。
- 按性别和年龄(≤75岁 vs. >75岁)分层分析结果保持一致。
临床怎么用
- 老年人首次选择抗抑郁药时可参考不同药物的真实世界结局差异进行获益-风险评估。
- 舍曲林在丹麦指南中为一线推荐,本研究以其为参照显示多数其他药物结局更差。
- 米氮平和文拉法辛使用者不良结局最多,提示应谨慎选用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The authors investigated the clinical outcomes of commonly used antidepressants among older adults who initiated first-time antidepressants for depression by analyzing the 1-year risk of selected clinically relevant outcomes. METHODS: This cohort study used nationwide Danish registry data and included all older adults who redeemed a first-time (since 1995) antidepressant prescription with an indication of depression between 2006 and 2017. Only the 10 most frequently redeemed antidepressants were included in the analyses. Outcomes included discontinuation, switching, augmentation, psychiatric hospital contacts, suicide attempt or self-harm, fall-related injuries, cardiovascular events, and all-cause mortality. Incidence rate ratios (IRRs) and 95% confidence intervals were estimated using Poisson regression models, controlling for potential confounders. RESULTS: The study sample included 93,883 older adults (mean age, 78.0 years, SD=7.5 years; 56% female). The most frequently prescribed antidepressants were selective serotonin reuptake inhibitors (citalopram, 47.04%; escitalopram, 11.81%; fluoxetine, 0.55%; paroxetine, 0.52%; sertraline, 11.17%), serotonin-norepinephrine reuptake inhibitors (duloxetine, 0.71%; venlafaxine, 1.54%), a tricyclic antidepressant (amitriptyline, 1.86%), and two atypical antidepressants (mianserin, 1.93%; mirtazapine, 22.87%). Compared with users of sertraline (the reference drug in this analysis, as Danish guidelines recommend it as the first-choice treatment for depression), users of most of the other nine antidepressants had a significantly higher risk of discontinuation (e.g., mirtazapine: IRR=1.55, 95% CI=1.50-1.61; venlafaxine: IRR=1.22, 95% CI=1.12-1.32), switching (amitriptyline: IRR=1.45, 95% CI=1.15-1.81; venlafaxine: IRR=1.47, 95% CI=1.20-1.80), augmentation, cardiovascular events, and mortality. Overall, mirtazapine and venlafaxine users had the most adverse outcomes compared with sertraline users. These results remained consistent in analyses stratified by sex and age (≤75 years vs. >75 years). CONCLUSIONS: This real-world evidence suggests that clinical outcomes may vary among initiators of commonly used antidepressants in older adults, which may inform benefit-risk evaluation at treatment initiation, and highlights the importance of careful selection of antidepressant treatment.
引用
- Ishtiak-Ahmed K, Musliner KL, Christensen KS, et al. Real-World Evidence on Clinical Outcomes of Commonly Used Antidepressants in Older Adults Initiating Antidepressants for Depression: A Nationwide Cohort Study in Denmark. Am J Psychiatry. 2023. PMID: 37849303. doi:10.1176/appi.ajp.20230356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。